Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. (Q53564370)

15 May 2018

title

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. (English)

1 reference

15 May 2018

1 reference

1 reference

15 May 2018

author name string

S Gurubhagavatula

1 reference

15 May 2018

W Zhou

1 reference

15 May 2018

Z Wang

1 reference

15 May 2018

B Y Yeap

1 reference

15 May 2018

K Asomaning

1 reference

15 May 2018

L Su

1 reference

15 May 2018

R Heist

1 reference

15 May 2018

T J Lynch

1 reference

15 May 2018

D C Christiani

1 reference

15 May 2018

publication date

20 March 2007

1 reference

15 May 2018

The Pharmacogenomics Journal

published in

1 reference

15 May 2018

volume

1 reference

15 May 2018

issue

1 reference

15 May 2018

page(s)

129-138

1 reference

15 May 2018

Gefitinib--a novel targeted approach to treating cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

A comparison of linkage disequilibrium measures for fine-scale mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

inferred from DOI database lookup

7 January 2021

based on heuristic

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500444

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.TPJ.6500444

1 reference

15 May 2018

1 reference

15 May 2018